

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person* ABERCROMBIE GEORGE B (Last) (First) (Middle) C/O BRICKELL BIOTECH, INC., 5777 CENTRAL AVENUE, SUITE 102 (Street) BOULDER, CO 80301 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 08/31/2019	3. Issuer Name and Ticker or Trading Symbol Brickell Biotech, Inc. [BBI]		
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below)		5. If Amendment, Date Original Filed(Month/Day/Year) 09/09/2019
		6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person		

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	7,230	D	
Common Stock	12,082	I	By Spouse as Trustee
Common Stock	12,082	I	By Spouse as Trustee
Common Stock	107,030	I	By Self As Trustee

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Options	01/25/2011	01/25/2021	Common Stock	8,630	\$ 2.9	D	
Stock Options	02/14/2014	02/14/2024	Common Stock	2,589	\$ 6.37	D	
Stock Options	04/22/2015	04/22/2025	Common Stock	8,630	\$ 12.17	D	
Stock Options	12/15/2016	12/15/2026	Common Stock	3,452	\$ 12.17	D	
Stock Options	12/15/2019	12/15/2028	Common Stock	5,178	\$ 16.45	D	
Stock Options	08/30/2020	08/30/2029	Common Stock	34,521	\$ 4.76	D	
Warrants	08/30/2019	08/30/2019	Common Stock	3,316	\$ 10.36	D	

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
ABERCROMBIE GEORGE B C/O BRICKELL BIOTECH, INC. 5777 CENTRAL AVENUE, SUITE 102 BOULDER, CO 80301	X			

Signatures

/s/ George B. Abercrombie		11/08/2019
**Signature of Reporting Person		Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.